Shares of Hims & Hers Health Inc (NYSE:HIMS) surged 11% in premarket trading on Thursday, extending gains after a 14% rise in the previous session.
The upward move came after comments from Health and Human Services Secretary Robert F. Kennedy Jr., who indicated that the Food and Drug Administration is in the process of removing 12 peptides from Category 2 restrictions.
Back in 2025, Hims & Hers expanded its capabilities by acquiring a manufacturing facility in California, aiming to grow its range of peptide-based treatments, including products focused on weight management and muscle recovery.